Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0
|
作者：
Macarulla, Teresa Mercade
Hubner, Richard
Blanc, Jean-Frederic
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew Peter
Yanshen, Shan
Jameson, Gayle S.
Lee, Kyung-Hun
Chiu, Chang-Fang
Schwartsmann, Gilberto
Braiteh, Fadi S.
Cunningham, David
Chen, Li-Tzong
Von Hoff, Daniel D.
Mamlouk, Khalid Kevin
de Jong, Floris A.
Siveke, Jens T.
机构：
[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France
[4] Washington Univ, Sch Med St Louis, St Louis, MO USA
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Szent Laszlo Teaching Hosp, Budapest, Hungary
[7] St John God Hosp, Subiaco, WA, Australia
[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[10] Seoul Natl Univ Hosp, Seoul, South Korea
[11] China Med Univ First Hosp, Taichung, Taiwan
[12] Fed Univ, Porto Alegre, RS, Brazil
[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA
[14] Royal Marsden NHS Fdn Trust, London, England
[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
[16] Ipsen Biosci Inc, Cambridge, MA USA
[17] Shire GmbH, Zug, Switzerland
[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.410
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
410
引用
收藏
页数：1
相关论文
共 49 条
  • [31] Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Pelzer, U.
    Blanc, J. -F
    Melisi, D.
    Cubillo, A.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Siveke, J. T.
    Wan, Y.
    Solem, C. T.
    Botteman, M.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 260 - 260
  • [32] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Yoo, C.
    Kim, K-P.
    Kim, I.
    Kang, M. J.
    Cheon, J.
    Kang, B. W.
    Ryu, H.
    Jeong, J.
    Lee, J. S.
    Kim, K. W.
    Ryoo, B-Y.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S565
  • [33] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Kim, I-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1464 - S1464
  • [34] Nomogram for Predicting Overall Survival in Patients Treated With Liposomal Irinotecan +/- 5-Fluorouracil/Leucovorin in Metastatic Pancreatic Ductal Adenocarcinoma Previously Treated With Gemcitabine-Based Therapy in NAPOLI-1
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 14 - 14
  • [35] A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).
    Dean, Andrew Peter
    Wainberg, Zev A.
    Ramanathan, Ramesh K.
    Boland, Patrick McKay
    Mody, Kabir
    Zhang, Bin
    Belanger, Bruce
    de Jong, Floris A.
    Braun, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
    Uwe Pelzer
    Jean-Frédéric Blanc
    Davide Melisi
    Antonio Cubillo
    Daniel D Von Hoff
    Andrea Wang-Gillam
    Li-Tzong Chen
    Jens T Siveke
    Yin Wan
    Caitlyn T Solem
    Marc F Botteman
    Yoojung Yang
    Floris A de Jong
    Richard A Hubner
    British Journal of Cancer, 2017, 116 : 1247 - 1253
  • [37] Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
    Pelzer, Uwe
    Blanc, Jean-Frederic
    Melisi, Davide
    Cubillo, Antonio
    Von Hoff, Daniel D.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Wan, Yin
    Solem, Caitlyn T.
    Botteman, Marc F.
    Yang, Yoojung
    de Jong, Floris A.
    Hubner, Richard A.
    BRITISH JOURNAL OF CANCER, 2017, 116 (10) : 1247 - 1253
  • [38] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
    Hubner, R.
    Cubillo, A.
    Blanc, J. -F.
    Melisi, D.
    Von Hoff, D.
    Wang-Gillam, A.
    Chen, L. -T.
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    De Jong, F.
    Siveke, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 119 - 119
  • [39] Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/IN in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
    Chen, Li-Tzong
    Siveke, Jens T.
    Wang-Gillam, Andrea
    Hubner, Richard
    Pant, Shubham
    Dragovich, Tomislav
    Chung, Vincent M.
    Chang, David Z.
    Ross, Paul J.
    Cooray, Prasad
    Tebbutt, Niall C.
    Franke, Fabio A.
    Belanger, Bruce
    Dhindsa, Navreet
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Li, Chung-Pin
    Wang-Gillam, Andrea
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Shan, Yan-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345